Ji Luo

List of Publications by Year in Descending Order

63 papers	11,344 citations	36 h-index	66 g-index
66 ext. papers	12,868 ext. citations	15.3 avg, IF	6.28 L-index

#	Paper	IF	Citations
63	A systematic genome-wide mapping of oncogenic mutation selection during CRISPR-Cas9 genome editing. *Nature Communications*, **2021**, 12, 6512	17.4	8
62	Metabolic supervision by PPIP5K, an inositol pyrophosphate kinase/phosphatase, controls proliferation of the HCT116 tumor cell line. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	2
61	KRAS mutation in pancreatic cancer. *Seminars in Oncology*, **2021**, 48, 10-18	5.5	10
60	Systematic exploration of different E3 ubiquitin ligases: an approach towards potent and selective CDK6 degraders. *Chemical Science*, **2020**, 11, 3474-3486	9.4	44
59	MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 4508-4517	11.5	63
58	Multiplexed CRISPR/Cas9 gene knockout with simple crRNA:tracrRNA co-transfection. *Cell and Bioscience*, **2019**, 9, 41	9.8	8
57	The Achilles Heel of Malignant Rhabdoid Tumors. *Cancer Research*, **2019**, 79, 2808-2809	10.1	
56	Genome-Wide RNAi Screen Identifies PMPCB as a Therapeutic Vulnerability in EpCAM Hepatocellular Carcinoma. *Cancer Research*, **2019**, 79, 2379-2391	10.1	10
55	Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy. *Molecular Systems Biology*, **2019**, 15, e8323	12.2	11
54	Tau Positron-Emission Tomography in Former National Football League Players. *New England Journal of Medicine*, **2019**, 380, 1716-1725	59.2	95
53	The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status. *Nature Communications*, **2019**, 10, 5428	17.4	12
52	Differential Effector Engagement by Oncogenic KRAS. *Cell Reports*, **2018**, 22, 1889-1902	10.6	66
51	Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4 T cell apoptosis promoting HCC development. *Cell Death and Disease*, **2018**, 9, 620	9.8	45
50	Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation. *Science Signaling*, **2018**, 11,	8.8	18
49	Genetic interrogation of replicative senescence uncovers a dual role for USP28 in coordinating the p53 and GATA4 branches of the senescence program. *Genes and Development*, **2017**, 31, 1933-1938	12.6	18
48	CRISPR/Cas9-mediated gene knockout is insensitive to target copy number but is dependent on guide RNA potency and Cas9/sgRNA threshold expression level. *Nucleic Acids Research*, **2017**, 45, 12039-12053	29.1	41
47	Global Inhibition with Specific Activation: How p53 and MYC Redistribute the Transcriptome in the DNA Double-Strand Break Response. *Molecular Cell*, **2017**, 67, 1013-1025.e9	17.6	36

46	Flexible CRISPR library construction using parallel oligonucleotide retrieval. *Nucleic Acids Research*, **2017**, 45, e101	20.1	4
45	A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers. *Oncotarget*, **2016**, 7, 10696-709	3.3	14
44	One-step immortalization of primary human airway epithelial cells capable of oncogenic transformation. *Cell and Bioscience*, **2016**, 6, 57	9.8	8
43	NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. *Nature*, **2016**, 531, 253-7	50.4	367
42	SUMO wrestling with Ras. *Small GTPases*, **2016**, 7, 39-46	2.7	4
41	Enhancer of rudimentary homolog regulates DNA damage response in hepatocellular carcinoma. *Scientific Reports*, **2015**, 5, 9357	4.9	19
40	Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, E1724-33	11.5	48
39	Activation of RAF1 (c-RAF) by the Marine Alkaloid Lasonolide A Induces Rapid Premature Chromosome Condensation. *Marine Drugs*, **2015**, 13, 3625-39	6	11
38	LAMC2 enhances the metastatic potential of lung adenocarcinoma. *Cell Death and Differentiation*, **2015**, 22, 1341-52	12.7	59
37	High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis. *Oncotarget*, **2015**, 6, 11694-703	3.3	47
36	Development of siRNA payloads to target KRAS-mutant cancer. *Cancer Discovery*, **2014**, 4, 1182-1197	24.4	68
35	Drugging the undruggable RAS: Mission possible?. *Nature Reviews Drug Discovery*, **2014**, 13, 828-51	64.1	1081
34	A high-throughput assay for small molecule destabilizers of the KRAS oncoprotein. *PLoS ONE*, **2014**, 9, e103836	3.7	16
33	Selective targeting of KRAS-mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-mutant cells. *Oncotarget*, **2014**, 5, 7635-50	3.3	17
32	Using pooled miR30-shRNA library for cancer lethal and synthetic lethal screens. *Methods in Molecular Biology*, **2014**, 1176, 45-58	1.4	1
31	Synthetic lethal genetic screens in Ras mutant cancers. *The Enzymes*, **2013**, 34 Pt. B, 201-19	2.3	5
30	Recurrent hemizygous deletions in cancers may optimize proliferative potential. *Science*, **2012**, 337, 104-9	33.3	148
29	Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 5322-7	11.5	556

28	A primer on using pooled shRNA libraries for functional genomic screens. *Acta Biochimica Et Biophysica Sinica*, **2012**, 44, 103-12	2.8	22
27	Cancer's sweet tooth for serine. *Breast Cancer Research*, **2011**, 13, 317	8.3	25
26	The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling. *Cancer Research*, **2010**, 70, 5305-15	10.1	105
25	Class IA phosphatidylinositol 3-kinase in pancreatic β cells controls insulin secretion by multiple mechanisms. *Cell Metabolism*, **2010**, 12, 619-32	24.6	84
24	Phosphatidyl inositol 3-kinase signaling in hypothalamic proopiomelanocortin neurons contributes to the regulation of glucose homeostasis. *Endocrinology*, **2009**, 150, 4874-82	4.8	74
23	Male-biased effects of gonadotropin-releasing hormone neuron-specific deletion of the phosphoinositide 3-kinase regulatory subunit p85alpha on the reproductive axis. *Endocrinology*, **2009**, 150, 4203-12	4.8	10
22	Principles of cancer therapy: oncogene and non-oncogene addiction. *Cell*, **2009**, 136, 823-37	56.2	1328
21	A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. *Cell*, **2009**, 137, 835-48	56.2	784
20	Cancer proliferation gene discovery through functional genomics. *Science*, **2008**, 319, 620-4	33.3	323
19	Acute effects of leptin require PI3K signaling in hypothalamic proopiomelanocortin neurons in mice. *Journal of Clinical Investigation*, **2008**, 118, 1796-805	15.9	259
18	Class 1A PI3K regulates vessel integrity during development and tumorigenesis. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 9739-44	11.5	93
17	The p85alpha regulatory subunit of phosphoinositide 3-kinase potentiates c-Jun N-terminal kinase-mediated insulin resistance. *Molecular and Cellular Biology*, **2007**, 27, 2830-40	4.8	66
16	T-cell function is partially maintained in the absence of class IA phosphoinositide 3-kinase signaling. *Blood*, **2007**, 109, 2894-902	2.2	50
15	Non-oncogene addiction and the stress phenotype of cancer cells. *Cell*, **2007**, 130, 986-8	56.2	272
14	Phosphoinositide 3-kinase regulatory subunit p85alpha suppresses insulin action via positive regulation of PTEN. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 12093-7	11.5	131
13	Sjögren's syndrome-like disease in mice with T cells lacking class 1A phosphoinositide-3-kinase. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 16882-7	11.5	63
12	Wortmannin-C20 conjugates generate wortmannin. *Journal of Medicinal Chemistry*, **2006**, 49, 740-7	8.3	19
11	Loss of class IA PI3K signaling in muscle leads to impaired muscle growth, insulin response, and hyperlipidemia. *Cell Metabolism*, **2006**, 3, 355-66	24.6	78

10	Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda/zeta. *Cell Metabolism*, **2006**, 3, 343-53	24.6	230
9	The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. *Nature Reviews Genetics*, **2006**, 7, 606-19	30.1	2416
8	Synthesis and activity of C11-modified wortmannin probes for PI3 kinase. *Bioconjugate Chemistry*, **2005**, 16, 669-75	6.3	16
7	Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. *Cancer Research*, **2005**, 65, 10992-1000	10.1	415
6	Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy. *Molecular and Cellular Biology*, **2005**, 25, 9491-502	4.8	170
5	The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex. *Journal of Cell Biology*, **2005**, 170, 455-64	7.3	126
4	The negative regulation of phosphoinositide 3-kinase signaling by p85 and its implication in cancer. *Cell Cycle*, **2005**, 4, 1309-12	4.7	83
3	Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 10238-43	11.5	39
2	Targeting the PI3K-Akt pathway in human cancer: rationale and promise. *Cancer Cell*, **2003**, 4, 257-62	24.3	1101
1	Phosphoinositide biology - messages from lipids. *Nature Cell Biology*, **2000**, 2, E190	23.4	